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Summary
 
A high proportion of tumors arise due to mutation of the p53 tumor suppressor protein. A p53
hotspot mutation at amino acid position 273 from R to H, flanking a peptide epitope that spans
residues 264–272, renders cells resistant to killing by human histocompatibility leukocyte anti-
gen (HLA)-A*0201–restricted cytotoxic T lymphocytes (CTLs) specific for this epitope. Ac-
quisition of the R to H mutation at residue 273 of the human p53 protein promotes tumor
growth in vivo by selective escape from recognition by p53.264–272 peptide-specific CTLs.
Synthetic 27-mer p53 polypeptides covering the antigenic nonamer region 264–272 of p53
were used as proteasome substrates to investigate whether the R to H mutation at the P1
 
9
 
 po-
sition of the COOH terminus of the epitope affects proteasome-mediated processing of the
protein. Analysis of the generated products by tandem mass spectrometry and the kinetics of
polypeptide processing in conjunction with CTL assays demonstrate that the R to H mutation
alters proteasomal processing of the p53 protein by inhibiting proteolytic cleavage between res-
idues 272 and 273. This prevents the release of the natural CTL epitope that spans flanking res-
idues 264–272 as well as a putative precursor peptide. These results demonstrate that mutation
of p53 not only leads to malignant transformation but may also, in some instances, affect im-
mune surveillance and should be considered in the design of cancer vaccines.
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I
 
nactivation of the p53 tumor suppressor protein, through
mutation or deletion, occurs in the majority of human
cancers (1, 2). Often this involves a missense mutation at
one of several defined mutational hotspots in the molecule
(1–3). The altered p53 protein accumulates to high levels
within the cell and has been used as a marker for malignant
transformation (1, 2). Previous studies in both murine and
human (Hu)
 
1
 
 models have demonstrated the preferential
susceptibility of transformed cells to lysis by CTLs that are
 
specific for peptides representative of processed wild-type
(WT) p53 protein sequences and are presented on the cell
surface by class I MHC molecules (4–9). Using transgenic
(Tg) mice that express the HLA-A
 
*
 
0201 (A
 
*
 
0201) mole-
cule, we previously identified two peptide sequences from
the Hu WT p53 molecule, p53.149–157 and 264–272, that
bind A
 
*
 
0201 and serve as endogenously processed target
epitopes for CTL recognition and lysis (4). Importantly,
CTLs specific for these p53-derived peptide epitopes are
able to recognize and lyse a broad range of p53-overex-
pressing and A
 
*
 
0201
 
1
 
 Hu tumor cells (4). In contrast, non-
transformed cells expressing A
 
*
 
0201 are not killed by the
same CTLs, presumably due to insufficient levels of expres-
sion of p53 and p53-derived CTL epitopes (4, 8). These
peptide epitopes are also able to stimulate A
 
*
 
0201-restricted
 
1
 
Abbreviations used in this paper:
 
 A
 
*
 
0201, HLA-A
 
*
 
0201; 
 
b
 
2
 
m, 
 
b
 
2
 
 micro-
globulin; ER, endoplasmic reticulum; Hu, human; MS, mass spectrome-
try; MS/MS, tandem mass spectrometry; 
 
m/z
 
, mass/charge; RP, reversed
phase; rVV, recombinant vaccinia virus; Tg, transgenic; WT, wild type.
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CTLs from Hu peripheral blood, suggesting the presence
of CTL precursors with specificity for p53 that may be po-
tentially mobilized to destroy tumor cells expressing high
levels of p53 peptides (10–13).
Peptides that are presented on the cell surface by class I
MHC molecules for recognition by CTLs most often are
derived from proteolytic processing of cellular proteins by
the multicatalytic proteasome complex (14–16). Proteolytic
degradation of p53 has been found to be dependent on
proteasomal processing (17–20). Proteasome-generated pep-
tide products are subsequently translocated into the endo-
plasmic reticulum (ER) by the transporters associated with
antigen processing, where they are loaded into the peptide-
binding groove of nascent class I molecules (21–23). In this
report, we demonstrate that proteasomal processing of the
natural A
 
*
 
0201-restricted CTL epitope p53.264–272 and
of a putative precursor peptide is profoundly affected by a
mutational p53 hotspot (R to H) at the COOH-terminal
flanking residue 273. As a consequence, target cells that
overexpress p53 harboring the 273 R to H mutation are
not susceptible to in vitro and in vivo lysis by A
 
*
 
0201-
restricted CTLs specific for the flanking p53 epitope, 264–
272. To our knowledge, these experiments demonstrate
the first example of a naturally occurring mutation flanking
a CTL epitope and affecting the ability of the proteasome
to generate a defined MHC class I ligand.
 
Materials and Methods
 
Mice.
 
The derivation of homozygous A2/K
 
b
 
-Tg mice ex-
pressing a chimeric transgene that consists of the 
 
a
 
1 and 
 
a
 
2 do-
mains of A
 
*
 
0201 and the 
 
a
 
3 domain of H-2K
 
b
 
 has been described
previously (4, 8). Mice were propagated and maintained under
specific pathogen–free conditions. All experimental procedures
were performed according to the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
 
Peptides.
 
27-mer polypeptides spanning residues 256–282 of
Hu WT (TLEDSSGNLLGRNSFEV
 
R
 
VCACPGRDR) and mu-
tant (273 
 
R
 
 to 
 
H
 
) p53 were synthesized on an automated peptide
synthesizer (432A; PE Applied Biosystems, Foster City, CA).
Peptides p53.264–272 (LLGRNSFEV) and 260–272 (SSGN-
LLGRNSFEV) were synthesized by the core facility of TSRI
(430A synthesizer; PE Applied Biosystems). Purity of synthetic
peptides was ascertained by reverse phase (RP)-HPLC and mass
spectrometry (MS). Amino acid residues are given in single letter
code.
 
Cell Lines.
 
Previously described cell lines and transfectants
used in these studies included T1 and T2 cells (24), the naturally
A
 
*
 
0201-expressing, p53-deficient osteosarcoma line Saos-2, and
the same cells transfected with Hu p53 genes harboring mutations
at residue 143 (V to A), 175 (R to H), and 273 (R to H) (4, 25).
Murine thymoma lines (EL4) transfected with A
 
*
 
0201/K
 
b
 
 (EA2K
 
b
 
)
or both A
 
*
 
0201/K
 
b
 
 and a Hu p53 gene harboring an R to H mu-
tation at residue 273 (EA2K
 
b
 
.1p53) have been generated as previ-
ously reported (8).
 
CTL Lines.
 
The derivation and maintenance of A
 
*
 
0201-
restricted CTL lines specific for Hu WT p53.264–272 (CTL A2
264) and p53.149–157 (CTL A2 149) have previously been de-
scribed (4). CTL lines were used as effector cells at the indicated
E/T ratios in 
 
51
 
Cr
 
-release assays (4).
 
Viral p53 Recombinants.
 
The derivation of parental canarypox
virus and canarypox virus p53 recombinants expressing Hu p53
without (WT) or with mutations at residue 175 (R to H) or 273
(R to H) has been previously described (5). Saos-2 targets were
labeled with 
 
51
 
Cr and infected with parental and recombinant ca-
narypox viruses at an infectious dose of 20 PFU/cell. Cells were
washed after 1 h and incubated for another 3-h period before
responder CTLs were added for a 3-h 
 
51
 
Cr-release assay (4). Re-
combinant vaccinia viruses (rVV) which contain minigenes encod-
ing either p53.149–157 (rVV-ES149) or p53.264–272 (rVV-
ES264) downstream of the ER insertion sequence of E19 (26), and
rVV-VPE16 that expresses the gp160 gene of HIV type 1 (27),
were provided by Drs. Jack Bennink and Jonathan Yewdell (Na-
tional Institute of Allergy and Infectious Diseases, Bethesda, MD).
 
Protection of Tumor Growth in A2/K
 
b
 
-Tg Mice.
 
A2/K
 
b
 
-Tg mice
were either nonimmunized or immunized intravenously with 5 
 
3
 
10
 
6
 
 PFU of rVV-ES149, rVV-ES264, or rVV-VPE16. 2 wk later,
mice were challenged subcutaneously in the right flank with 5 
 
3
 
10
 
5
 
 EA2K
 
b
 
 or EA2K
 
b
 
.1p53 tumor cells. The size of tumors was
determined by the formula (a
 
2
 
 
 
3 
 
b/2), in which 
 
a
 
 defines the hor-
izontal and 
 
b
 
 the vertical diameter of the tumor mass as deter-
mined by calipers. Three mice were used for each experimental
and control group.
 
Purification of 20S Proteasomes.
 
20S proteasomes were purified
from Hu T1 cells by standard procedures (28–31). Cell pellets
were lysed in lysis buffer (80 mM KAc, 5 mM MgAc
 
2
 
, 10 mM
Hepes, pH 7.2, and 0.1% Triton X-100), dounce homogenized,
and spun at 40,000 
 
g
 
 for 20 min. Supernatant was adsorbed to
equilibrated DEAE-Sephacel (Amersham Pharmacia Biotech, Pis-
cataway, NJ) for 45 min, unbound protein was removed with
wash buffer (80 mM KAc, 5 mM MgAc
 
2
 
, and 10 mM Hepes, pH
7.2), and bound protein was eluted (500 mM KAc, 5 mM MgAc
 
2
 
,
and 10 mM Hepes, pH 7.2). The protein containing eluate was
concentrated by ultrafiltration, loaded on a 10–40% sucrose gradi-
ent in wash buffer, and ultracentrifuged (40,000 rounds/min in an
SW40 Ti rotor for 15.5 h; Beckman, Fullerton, CA). Gradient
fractions containing 20S proteasome complexes were identified
by enzyme assays using fluorogenic substrate peptides, pooled,
and concentrated for chromatography on a MonoQ HR 5/5 an-
ion exchange column (Amersham Pharmacia Biotech; eluent A:
100 mM KCl, 5 mM MgCl
 
2
 
, and 10 mM Hepes, pH 7.2; eluent
B: 1 M KCl, 5 mM MgCl
 
2
 
, and 10 mM Hepes, pH 7.2; linear
gradient). The 20S proteasomes obtained were again identified by
enzymatic activity and eluted as single peak upon rechromato-
graphy. Purity of 20S proteasome preparations was 
 
.
 
90% as as-
sessed by Coomassie-stained PAGE gels. Two-dimensional gel
electrophoresis revealed that all detectable proteasomal subunits
were present in 20S proteasomes purified from the Hu T1 cell line.
 
In Vitro Digestion of Polypeptide Substrates by Purified 20S Protea-
somes and Recognition by CTLs.
 
20 
 
m
 
g of synthetic 27-mer p53
polypeptide substrates were incubated for the indicated periods of
time at 37
 
8
 
C with and without 1 
 
m
 
g of purified 20S proteasome
in a total volume of 300 
 
m
 
l of assay buffer consisting of 20 mM
Hepes-KOH, pH 7.8, 2 mM MgAc
 
2
 
, and 1 mM dithiothreitol
(28–31). 
 
51
 
Cr-labeled T2 cells were pulsed for 30 min with de-
graded 27-mer peptide products at the indicated concentrations
in serum-free RPMI 1640 medium supplemented with 5% vol/
vol BSA and Hu 
 
b
 
2
 
 microglobulin (
 
b
 
2
 
m) at 10 
 
m
 
g/ml. CTL A2
264 and CTL A2 149 were used as effector cells at an E/T ratio
of 20:1 in a 6-h 
 
51
 
Cr-release assay.
 
Peptide Analysis by MS.
 
10 
 
m
 
l of 20S proteasome degraded
peptide digests were separated by a RP-HPLC SMART-System
equipped with a 
 
m
 
RPC C2/C18 SC 2.1/10 column (Amersham 
1019
 
Theobald et al.
Pharmacia Biotech) and eluted with a gradient of 15–65% of elu-
ent B (70% acetonitrile in 0.05% TFA) in eluent A (0.05% TFA)
in 33 min at a flow rate of 50 
 
m
 
l/min (29–31). Mass analysis of
peptides was performed online by a tandem quadrupole mass
spectrometer (TSQ 7000; Finnigan MAT, San Jose, CA) equipped
with an electrospray ion source. Each scan was acquired over the
range mass/charge (
 
m/z
 
) 300–1150 every 2 s (29–31). Peptides
were identified by their molecular mass calculated according to the
 
m/z
 
 peaks of single or multiple charged ions. Abundant peptides
with signal intensities of at least threefold above background were
sequenced by tandem MS (MS/MS) after fragmentation of the rel-
evant peptides with argon atoms (30). Peptide sequence was deter-
mined from the masses of the fragmented peptide ions.
 
HPLC Separation of Processed Peptides, Identification by CTLs, and
Sequence Analysis of Antigenic Peptides by MS/MS.
 
50 
 
m
 
l of the
bulk 20S proteasome degraded peptide products were separated
by RP-HPLC into 1- (50 
 
m
 
l) and 0.5- (25 
 
m
 
l) min fractions (30).
 
51
 
Cr-labeled T2 target cells were pulsed for 40 min with half of
each of the HPLC fractions in serum-free RPMI 1640 medium
supplemented with 5% vol/vol BSA and Hu 
 
b
 
2
 
m at 10 
 
m
 
g/ml.
CTL A2 264 were used as effector cells at an E/T ratio of 20:1 in
a 6-h 
 
51
 
Cr-release assay. The antigenic HPLC fractions were
dried and resuspended in 50% methanol/1% acetic acid. Anti-
genic peptides present in the pooled HPLC fractions were identi-
fied by coelution of synthetic peptides and sequenced by MS/MS
(30). Ions of 
 
m/z
 
 corresponding to the relevant double proto-
nated peptides were fragmented by argon atoms. Collision-acti-
vated dissociation fragments of relevant m/z and derived from the
pooled antigenic HPLC fractions were compared with those ob-
tained after argon atom–mediated fragmentation of the corre-
sponding synthetic peptides.
Extraction of Natural Peptides from Class I MHC Molecules. Ad-
herent Saos-2/143 p53 transfectants were grown at z107 cells/
flask. Cells were washed twice with HBSS, and class I MHC–
bound peptides were extracted by exposing cells for 1 min in 5 ml
of buffer consisting of 0.13 M citric acid and 0.061 M Na2HPO4
at pH 3.0 (32–34). Cells were washed twice in RPMI 1640 and
recultured in complete medium. Extracts were spun and the pep-
tide containing supernatant was frozen. This procedure was re-
peated every other day for 3 wk to collect peptide extracts from
the equivalent of 1.2 3 109 Saos-2/143 cells. Extracts were
thawed, pooled, and loaded on C-18 spice cartridges (Analtech,
Inc., Newark, DE) that had been washed with 4 ml each of meth-
anol and H2O. Cartridges were again washed with H2O (10 ml) and
peptides were eluted with 4 ml of 0.1% vol/vol TFA in acetoni-
trile. The peptide containing eluate was vacuum dried, resus-
pended in H2O, and cleared of debris by centrifugation. The su-
pernatant was filtered through Centricon-10 (Amicon, Beverly,
MA), and the resultant peptide extract was again vacuum dried.
HPLC Separation of Natural Peptide Extracts and Reconstitution of
CTL Lysis. 1 ml of resuspended natural peptide extract or 100
pmol of either the p53.264–272 or the p53.260–272 synthetic
peptides were separated by RP-HPLC at a flow rate of 50 ml/
min and eluted with a gradient of 20% of eluent B (70% acetoni-
trile in 0.05% TFA) in eluent A (0.05% TFA) in 32 min, a gradi-
ent of 20–48% of eluent B in eluent A in 74 min, and a gradient
of 48–95% of eluent B in eluent A in 4 min. HPLC fractions
were collected from 32 to 76 min (fractions 1–11: 4 min fractions
at 200 ml/fraction) and from 76 min onwards (fractions 12–48: 1
min fractions at 50 ml/fraction). 51Cr-labeled T2 target cells were
pulsed for 40 min in serum-free RPMI 1640 medium supple-
mented with 5% vol/vol BSA and Hu b2m at 10 mg/ml with 100 ml
(fractions 4–11) or 25 ml (fractions 12–44) of fractions derived
from the HPLC separation of the natural peptide extract. The
corresponding volumes of fractions derived from the HPLC sepa-
rations of synthetic p53.264–272 and p53.260–272 peptides and
used to pulse T2 targets were 8 (fractions 4–11) and 2 ml (frac-
tions 12–44). CTL A2 264 were used as effector cells at an E/T
of 20:1 in a 5.5-h 51Cr-release assay. Antigenic fractions obtained
from the HPLC-separated natural peptide extract were pooled
and half of the pooled natural peptides was used for rechromatog-
raphy by RP-HPLC. HPLC conditions remained almost the
same, yet 0.5-min fractions were collected from 56 min onwards
(fractions 10–44 at 25 ml/fraction). The amount of synthetic
p53.264–272 and p53.260–272 peptides used for the second
HPLC separations was 60 pmol. 51Cr-labeled T2 target cells were
again pulsed for 40 min under serum-free conditions with 18 ml
of fractions 10–32 derived from the rechromatography of the
pooled antigenic natural HPLC fractions. The corresponding vol-
umes of fractions derived from the HPLC separations of the syn-
thetic p53.264–272 and p53.260–272 peptides and used to pulse T2
targets were 2 ml (fractions 8, 19, 20, 29) and 0.02 ml, 0.2 ml, and
2 ml (fractions 9–18 and 21–28), respectively. CTL A2 264 were
used as effector cells at an E/T of 13:1 in a 6-h 51Cr-release assay.
Results and Discussion
Target Cells Expressing a p53 Mutational Hotspot at Residue
273 Are Not Recognized by CTLs Specific for the Flanking
Epitope 264–272. The p53-deficient Saos-2 tumor cell
line transfected with a Hu p53 gene expressing the R to H
hot spot mutation at amino acid residue 273 was not sus-
ceptible to lysis by CTL A2 264 specific for the flanking
peptide 264–272 (Fig. 1 A). This contrasted with the suc-
cessful recognition and lysis of cells transfected with Hu
p53 genes expressing mutations at amino acid positions 143
or 175 (Fig. 1 A). All three p53 transfectants were killed by
CTLs specific for CTL A2 149, indicating that other
epitopes of the protein were being processed and presented
by the A*0201 molecule (Fig. 1 B). Furthermore, as dem-
onstrated in Fig. 1, C and D, Saos-2 cells infected with ca-
narypox virus recombinants expressing Hu p53 with or
without mutation at residue 175 were recognized by either
CTL, whereas cells infected with a canarypox virus p53 re-
combinant expressing the 273 R to H mutation were lysed
only by CTL A2 149 and not by CTL A2 264. Taken to-
gether, these results suggested that the R to H mutation at
position 273 of the p53 protein may have prevented forma-
tion of the 264–272 peptide epitope.
Acquisition of the R to H Mutation at Residue 273 Promotes
Tumor Growth In Vivo by Escape from Immune Recognition.
To determine if tumors that express Hu p53 harboring the
R to H mutation at residue 273 would be resistant to
growth inhibition by A*0201-restricted CTLs specific for
p53.264–272, A2/Kb-Tg mice were immunized with rVV
strains containing minigenes encoding the sequence of
either the Hu p53.149–157 (rVV-ES149) or the Hu
p53.264–272 peptide (rVV-ES264). Control mice either
received no vaccination or were immunized with rVV en-
coding the HIV type 1 envelope protein gp160 (rVV-
VPE16). 2 wk later, mice were challenged with syngeneic
EA2Kb or EA2Kb.1p53 transfectants, the latter of which1020 p53 Hotspot Retards Proteasomal Processing of a Flanking CTL Epitope
express the R to H mutation at residue 273 of Hu p53.
Preimmunization with rVV-ES149 specifically prevented
growth of EA2Kb.1p53 tumors, whereas vaccination with
rVV-ES264 did not (Fig. 2). Vaccination with either virus
led to equivalent priming of CTLs specific for the respec-
tive peptide (data not shown). Tumors that eventually grew
out in rVV-ES149 preimmunized mice were found to have
lost expression of Hu p53 protein (35). EA2Kb.1p53-derived
tumors in untreated or rVV-VPE16–vaccinated A2/Kb-Tg
mice progressed with the same growth rate as in rVV-ES264–
immunized animals (35). Tumor growth of the parental
EA2Kb cells, which express only low levels of murine WT
p53 (8), was not prevented by either vaccination (35).
These results indicate that tumors harboring the R to H
mutation at residue 273 of the Hu p53 protein are able to
selectively escape recognition in vivo by CTLs specific for
the flanking peptide 264–272.
Peptides Derived from 20S Proteasome Degradation of the
Synthetic 27-mer Polypeptide p53.256–282 Carrying an R to
H Mutation at Residue 273 Are Not Recognized by CTL A2
264. In several reports, it has been demonstrated that the
proteasome system represents a major source for the gener-
ation of MHC class I ligands (14–16, 28, 36). As demon-
strated previously, degradation of p53 is dependent on pro-
teasomal processing (17–20). Accordingly, one mechanism
that could interfere with the availability of the 264–272
epitope would be the inability of the proteasome to pro-
duce this peptide from the 273 R to H mutant p53. This
could arise if the COOH-terminal cleavage site of the 264–
272 epitope was abrogated by the change from R to H at the
epitope flanking residue 273. To test this hypothesis, syn-
thetic 27-mer p53 peptides spanning residues 256–282 and
containing the 264–272 epitope flanked by either the WT
or mutant residue at position 273 were used as substrates
for in vitro digestion by purified 20S proteasomes. T2 tar-
get cells that express predominantly empty A*0201 mole-
cules (24) were pulsed with the peptide digests and tested
for recognition by CTL A2 264. Substantial lysis of T2 tar-
gets was observed when cells were pulsed with peptides
derived from the 20S proteasome–degraded WT 27-mer,
but not with those derived from degraded mutant 27-mer
(Fig. 3). Recognition of the synthetic 9-mer p53.264–272
epitope as compared with the WT p53.256–282 peptide
digest was 2.4 logs more efficient (2.3–2.7 logs as compared
with three independent WT 27-mer peptide digests), sug-
Figure 1. Cells expressing Hu p53 that
contains an R to H mutation at residue 273
are resistant to lysis by A*0201-restricted
CTLs specific for the flanking peptide
epitope p53.264–272. A*0201-restricted
CTL lines specific for peptide epitopes
p63.264–272 (A2 264) (A and C) and
p53.149–157 (A2 149) (B and D) were
tested for cytotoxicity at the indicated E/T
ratios in 5-h (A and B) and 3-h (panel C
and D)  51Cr-release assays. Targets in A and
B were p53 deficient Saos-2 cells (s), and
the same cells transfected with Hu p53
genes harboring mutations at residue 143
(V to A) (d), 175 (R to H) (n), and 273 (R to H) (m). Targets in C and D were Saos-2 cells (s), the same cells infected with canarypox virus recombi-
nants expressing Hu p53 without (d) or with mutations at residue 175 (R to H) (n) and 273 (R to H) (m), and Saos-2 cells infected with the parental
canarypox virus (u).
Figure 2. Immunization of
A2/Kb-Tg mice with the
p53.264–272 epitope does not
prevent growth of tumor cells
expressing both A*0201/Kb and
Hu p53 containing an R to H
mutation at residue 273. A2/
Kb-Tg mice were immunized
intravenously with 5 3 106 PFU
of rVV-ES149 (s) or rVV-
ES264 (d). 2 wk later (day 0),
mice were challenged subcutane-
ously in the right flank with 5 3 105 EA2Kb.1p53 (273 R to H) tumor
cells. Nontreated or rVV-VPE16–vaccinated (encoding the HIV type 1
envelope protein gp160) A2/Kb-Tg mice behaved the same as rVV-
ES264–immunized animals; tumors appeared on day 10 after challenge
and progressed with the same growth rate. These negative controls are
not shown for clarity.
Figure 3. Peptide products
derived from in vitro 20S pro-
teasome degradation of the syn-
thetic 27-mer polypeptide
p53.256–282 carrying an R to H
mutation at residue 273 are not
recognized by CTLs specific for
the nonameric p53.264–272
peptide epitope. Synthetic 27-mer
polypeptide substrates spanning
residues 256–282 of WT
(TLEDSSGNLLGRNSFEVRV-
CACPGRDR) or mutant (273 R to H) p53 were incubated for 24 h with
and without purified 20S proteasome. 51Cr-labeled T2 cells were pulsed
under serum-free conditions with the indicated concentrations of WT
27-mer products that had been incubated with (d) and without (s) 20S
proteasome, mutant 27-mer products that had been incubated with (m)
and without (n) 20S proteasome, the synthetic p53.264–272 peptide
epitope (j), or no peptide (h). A*0201-restricted CTLs specific for the
p53.264–272 peptide epitope were used as effector cells at an E/T ratio of
20:1 in a 6-h 51Cr-release assay. Peptide concentration is given as the
equivalent of the input concentration of 27-mer polypeptide substrates
before proteasomal degradation (nM eq). Peptide-pulsed T2 targets were
not lysed by CTLs specific for the unrelated p53.149–157 peptide (data
not shown).1021 Theobald et al.
gesting that the 264–272 epitope did not represent an
abundant product generated from the WT 27-mer by the
20S proteasome. The selective recognition of WT as op-
posed to mutant 27-mer peptide digests by CTL A2 264
was dependent on degradation by the 20S proteasome as
no lysis was detectable when WT and mutant 27-mer pep-
tides were incubated in the absence of the 20S proteasome.
Kinetic studies revealed that WT degradation products rec-
ognized by T cells became detectable after 1 and 2 h of in-
cubation of the polypeptide with purified 20S proteasome
(Fig. 4, A and B), reached a peak of activity after a period
of between 5 and 8 h of proteasomal cleavage (Fig. 4, C
and D), and could still be observed after 27 h of protea-
some incubation (data not shown). These results indicate
that the R to H mutational change at residue 273 affected
the ability of the proteasome to release an antigenic peptide
from the 27-mer that could be recognized by CTL A2 264.
The p53 Mutation at Residue 273 Abrogates the Proteasomal
Cleavage Site between p53 Residues 272 and 273. To prove
that the COOH-terminal cleavage site of the 264–272
epitope has indeed been abrogated by the change from R to
H at flanking residue 273, the 20S proteasome–degraded
(24-h) WT and mutant p53.256–282 peptide products were
separated by RP-HPLC, abundant masses were identified
online by MS, and the sequence of abundant peptides was
confirmed by MS/MS. The majority of the dominant
cleavage products generated by the 20S proteasome from the
WT and mutant 27-mer polypeptides were comparable in
sequence and quantity (Fig. 5, A and B). However, within
the range of signal intensities of at least threefold above back-
ground, only two peptides, 260–272 and 256–272, both
of which contained the COOH-terminal residue 272 of
the CTL epitope 264–272, were observed (Fig. 5 A). Nota-
bly, the relative signal intensities of peptides 260–272 and
256–272 were found to be 14- and 20-fold higher, respec-
tively, within the WT as opposed to the mutant peptide
digests (Fig. 5, C and D, panels 2 and 3). The differential
detectability of these peptides within the WT as opposed to
the mutant 27-mer peptide digests was not due to differ-
ences in the efficiency of proteasomal degradation of either
polypeptide. In general, the efficiency of 20S proteasome–
induced degradation of either 27-mer peptide was .95%
(Fig. 5, C and D, panel 4). Also, comparable amounts (rela-
tive signal intensity: twofold more in mutant versus WT) of
the peptide 266–275, which did not use the relevant cleav-
age site between residues 272 and 273, were generated from
the WT and mutant 27-mer (Fig. 5, C and D, panel 1).
These results indicate that the p53 R to H mutation at
residue 273 retards proteolytic cleavage by the 20S protea-
some between residues 272 and 273. However, we could
not detect the peptide representing the CTL epitope 264–
272. The proteolytic generation of the 264–272 epitope
from the WT 27-mer at a quantity below the threshold of
detectability by MS could have been responsible for such
lack of detection, even though the bulk WT 27-mer degra-
dation products had been recognized by CTL A2 264. The
observation that the 266–275 peptide was an abundant pro-
teasomal cleavage product of both the WT and mutant 27-
mer substrate would support this interpretation, as the re-
lease of this peptide would interfere with the generation of
the 264–272 CTL epitope (Fig. 5). However, it could also
be possible that the peptide 260–272, which used the
COOH-terminal cleavage site between residues 272 and
273, represents a precursor peptide that is subsequently
trimmed in the cytosol or the ER to the size of the optimal
antigenic CTL epitope 264–272. Postproteasomal trim-
ming of the NH2 terminus of precursor peptides has been
observed previously (31, 37–40).
The p53.264–272 CTL Epitope Is Generated by Proteaso-
mal Degradation of the WT as Opposed to the Mutant 27-mer
Polypeptide Substrate. To improve the sensitivity of detec-
tion of the 264–272 peptide, the proteasome degraded
peptide products (24-h) were fractionated by RP-HPLC.
T2 targets were sensitized with the individual HPLC frac-
tions and tested for recognition by CTL A2 264. Only T2
cells that had been pulsed with fractions 24, 25, and 26 of
the WT 27-mer peptide digests were recognized by CTL
A2 264 (Fig. 6, A and B). The retention time of fraction 24
was matched by that of the synthetic 264–272 peptide (data
not shown). WT fractions 24 and 25 were pooled and
tested for the presence of the 264–272 peptide by MS/MS.
Identical collision-activated dissociation fragments of ions
corresponding to the double protonated 264–272 peptide
were detected in the pooled WT fractions 24 and 25, and
the synthetic 264–272 peptide (Fig. 6, C and D). The rele-
vant collision-activated dissociation fragments were absent
Figure 4. Kinetics of 20S proteasomal degra-
dation of WT and mutant 27-mer p53 polypep-
tide substrates. WT and mutant p53.256–282
peptide substrates were incubated for 1 (A), 2
(B), 5 (C), and 8 (D) h with and without puri-
fied 20S proteasome. 51Cr-labeled T2 cells were
pulsed under serum-free conditions with the in-
dicated concentrations of WT 27-mer products
that had been incubated with (d) and without
(s) 20S proteasome, and mutant 27-mer prod-
ucts that had been incubated with (m) and with-
out (n) 20S proteasome. Material derived from
the incubation of 20S proteasome in the absence of any polypeptide substrate served as another negative control (h). CTL A2 264 were used as effector
cells at an E/T ratio of 20:1 in a 6-h 51Cr-release assay. Peptide concentration is given as the equivalent of the input concentration of 27-mer polypeptide
substrates before proteasomal degradation (nM eq).1022 p53 Hotspot Retards Proteasomal Processing of a Flanking CTL Epitope
in pooled WT fractions 22 and 23, and in pooled mutant
fractions 22 and 23 and 24 and 25 (data not shown). These
results indicate that the p53.264–272 CTL epitope had
been generated directly from the WT 27-mer by the 20S
proteasome. Its low abundance is not unique, but a prop-
erty shared with immunodominant nonameric CTL epi-
topes detected in 20S proteasome in vitro digests (30, 41–
45). CTL assays of p53-deficient Saos-2 cells infected with
rVV expressing minigenes encoding either the 149–157 or
the 264–272 peptide without an ER insertion sequence re-
vealed that the 264–272 peptide is efficiently translocated
into the ER (Theobald, M., and L.A. Sherman, unpub-
lished observation). These findings demonstrate that the
p53 hotspot mutation from R to H at residue 273 prevents
the 20S proteasome–mediated COOH-terminal cleavage
of the flanking peptide 264–272 and its subsequent presen-
tation by A*0201.
The more abundant flanking peptide 256–272 eluted in
WT fraction 26, which was recognized poorly by CTL A2
264 (Figs. 5 A and 6 A), making it unlikely to be an inde-
pendent CTL epitope. However, it is of interest that due to
the HPLC conditions used, the other abundant flanking
peptide 260–272 (Fig. 5 A) was identified by MS/MS to be
present in the pooled WT fractions 24 and 25 (data not
shown). However, the A*0201-binding affinity of the
longer peptide 260–272 was 2.5-fold lower than that of the
9-mer 264–272, and it was found to be recognized 30–
100-fold less efficiently by CTL A2 264 (data not shown).
These results favor the view that 260–272 may represent a
precursor peptide that is eventually trimmed in the cytosol
or the ER to the 9-mer rather than functioning as an inde-
pendent CTL epitope.
The Hu WT p53.264–272 Peptide Is the Natural Epitope
Presented by A*0201 and Recognized by CTL A2 264. To
Figure 5. The p53 hotspot
mutation at residue 273 (R to H)
abrogates the proteasomal cleav-
age site between p53 residues
272 and 273. Bulk peptide prod-
ucts derived after 24 h from 20S
proteasome–mediated degrada-
tion of the synthetic WT (A and
C) and mutant (273 R to H) (B
and  D) 27-mer polypeptides
p53.256–282 covering the
A*0201-restricted CTL epitope
p53.264–272 (LLGRNSFEV)
were separated by RP-HPLC
and analyzed online by MS.
Abundant peptide products
were sequenced by MS/MS.
Cleavage products with signal
intensities of at least threefold
above background and identi-
fied by mass (MS) and sequence
(MS/MS) are shown in descend-
ing order according to their sig-
nal intensities (A and B, black
bars). The amino acid sequence
of WT (A) and mutant (B) pep-
tide substrates with abundant
(large arrows) and nonabundant
(small arrows) cleavage sites is also
presented. The small broken ar-
row (A) represents the theoreti-
cal NH2-terminal cleavage site of
the nonameric CTL epitope
264–272. The quantitative com-
parison of some of the relevant
WT (C) and mutant (D) cleav-
age products is shown by their
elution profiles and relative sig-
nal intensities as measured by the
ion current of double protonated
peptide ions. As demonstrated
in C and D, peptide 266–275
(GRNSFEV-R/H-VC) repre-
sents a dominant product that in-
terferes with the formation of the 264–272 CTL epitope (panel 1). The WT p53 peptides 260–272 (SSGNLLGRNSFEV) and 256–272 (TLEDSSGN-
LLGRNSFEV) use the COOH-terminal cleavage site of the minimal CTL epitope 264–272 between WT residues 272 and 273 (panels 2 and 3). Panel 4
shows the uncleaved WT and mutant 27-mer substrate peptides left after proteasomal degradation and used for adjusting the scale (percentage of relative
intensity). Panel 5 gives the total ion current of the bulk proteasomal degradation products.1023 Theobald et al.
identify the natural peptide epitope presented by A*0201
and recognized by CTL A2 264, peptides were extracted
from class I MHC molecules of Saos-2/143 p53 transfec-
tants. As the 9-mer (264–272) and 13-mer (260–272) p53
peptides had an almost identical retention time under the
HPLC conditions used for purifying the 20S proteasomal
peptide digests, a shallower elution gradient was applied for
the RP-HPLC fractionation of natural peptide extracts as
well as synthetic 9-mer and 13-mer peptides. The pool of
natural peptides extracted from Saos-2/143 cells was chro-
matographed by HPLC and 4-min fractions collected and
assayed. To obtain final resolution, antigenic fractions 7
and 8 were pooled and half of the pool was rechromato-
graphed. At the relevant retention time, 0.5 min fractions
were collected in order to discriminate between the 264–
272 and the 260–272 peptides. T2 cells sensitized with in-
dividual HPLC fractions served as targets for CTL A2 264.
As shown in Fig. 7 A, the peak of CTL activity obtained
after rechromatography of fractions 7/8 and derived from
the natural peptide extract was detected in fraction 12. This
HPLC fraction had the same conductivity and retention
time as compared with the antigenic fractions (12 and 13)
derived from the HPLC separation of the synthetic 264–
272 9-mer peptide (Fig. 7 B). In contrast, the antigenic ac-
tivity of the synthetic 260–272 13-mer peptide eluted in
fraction 24 and its retention time differed from the 264–
272 peptide by 6 min under the conditions used for re-
chromatography (Fig. 7 C). The lower amount of lysis ob-
tained with fraction 24 of the synthetic 260–272 peptide
again indicated less efficient crossrecognition by CTL A2
264. Pulsing T2 targets with a 10-fold higher amount (2 ml)
of fraction 24 of the synthetic 260–272 peptide resulted in
a substantial increase of lysis (100% specific lysis by CTL A2
26; (data not shown). However, as little as 0.02 ml of either
fraction 12 or 13 of the synthetic 264–272 peptide was suf-
ficient to detect substantial lysis (fractions 12 and 13: 50 and
61% specific lysis, respectively) of peptide-pulsed T2 cells
by CTL A2 264 (data not shown). No antigenic activity
could be observed with fraction 24 after rechromatography
of the natural peptide extract (Fig. 7 A). These results indi-
Figure 6. The p53.264–272
CTL epitope is generated by pro-
teasomal degradation of the WT
as opposed to the mutant 27-mer
p53.256–282 polypeptide sub-
strate. Bulk 20S proteasome–
degraded (24-h) WT and mutant
27-mer peptide products were
fractionated by RP-HPLC. 51Cr-
labeled T2 target cells were
pulsed for 40 min under serum-
free conditions with half of each
of the WT and mutant HPLC
fractions and tested for suscepti-
bility to lysis by CTL A2 264 at
an E/T ratio of 20:1 in a 6-h
51Cr-release assay. The HPLC
profile (absorbance: —) and the
specific lysis (shaded columns) of T2
targets sensitized with individual
WT (A) and mutant (B) HPLC
fractions is shown. WT fractions
24 and 25 were pooled and tested
by MS/MS for detection of the
p53.264–272 (LLGRNSFEV)
peptide epitope. Ions of m/z 5
517.2 corresponding to the dou-
ble protonated 264–272 9-mer
peptide were fragmented by ar-
gon atoms. Collision-activated
dissociation fragments of m/z
517.2 and derived from the
pooled WT fractions 24 and 25
(C) were compared with those
obtained after argon atom–medi-
ated fragmentation of the syn-
thetic 264–272 peptide (D). In
particular, fragments b8, b7, and
b6, lacking the COOH-terminal
residues V, E, and F, respectively,
were detectable in both the
pooled WT fractions 24 and 25
(C) and the synthetic 264–272
9-mer peptide (D).1024 p53 Hotspot Retards Proteasomal Processing of a Flanking CTL Epitope
cate that the Hu WT p53.264–272 as opposed to the longer
260–272 peptide is the natural epitope presented by A*0201
and recognized by CTL A2 264. However, as the 13-mer
260–272 (and the 17-mer 256–272) peptide(s) are the more
abundant products released from the WT p53 sequence by
the 20S proteasome (Fig. 5, A and C), it is possible that
these peptides undergo NH2-terminal trimming in the cyto-
sol or ER (37–40) and represent precursor peptides that may
thereby contribute substantially to the availability of the
low-abundant WT p53 processing product 264–272 for its
assembly with nascent A*0201 molecules in the ER.
Several recent studies have focused on the mutational al-
teration within a peptide epitope to demonstrate a way by
which viruses can escape recognition by epitope-specific
CTLs (46–50). This is generally believed to involve peptide
binding to the MHC class I molecule, or recognition by the
TCR (46–50). However, in a recent report it was shown
that a mutation within a viral peptide epitope affected the
production of precursor peptides by proteasomal degradation
through the introduction of a dominant new proteasomal
cleavage site within the viral epitope (31). Based on studies
that evaluated the effect of synthetically altering residues
Figure 7. The Hu WT p53.264–272
peptide is the natural epitope presented
by A*0201 for recognition by CTL A2
264. Natural peptides were extracted
from class I molecules of Saos-2/143
p53 transfectants. Synthetic p53.264–
272 and 260–272 peptides and the natu-
ral peptide extract were fractionated by
RP-HPLC. Individual HPLC fractions
were used to sensitize T2 targets and to
reconstitute lysis by CTL A2 264. Two
antigenic HPLC fractions obtained from
the natural peptide extract had an almost
identical retention time and conductiv-
ity as compared with those antigenic
HPLC fractions derived from the syn-
thetic p53.264–272 and p53.260–272
peptides. As 4-min HPLC fractions
were collected at the relevant retention
time, the peak of CTL activity occurred
in almost identical HPLC fractions, al-
though the retention time of the syn-
thetic p53.264–272 and p53.260–272
peptides differed from each other by z4
min. To separate either peptide from
one another and identify the natural an-
tigenic peptide, half of the pooled anti-
genic fractions of the HPLC-separated
natural peptide extract (A) as well as 60
pmol of synthetic 264–272 (B) and 260–
272 (C) peptides were used for rechro-
matography by RP-HPLC. HPLC con-
ditions remained almost the same, yet
0.5-min fractions (25 ml/fraction) were
collected at the relevant retention time
in order to discriminate between the
264–272 and the 260–272 peptides.
51Cr-labeled T2 target cells were pulsed
for 40 min under serum-free conditions
with individual HPLC fractions (frac-
tions derived from the rechromatogra-
phy of natural peptides: 18 ml; fractions
8, 19, 20, and 29 derived from synthetic
p53 peptides: 2 ml; fractions 9–18 and
21–28 derived from synthetic p53 pep-
tides: 0.02 ml, 0.2 ml, and 2 ml) and
tested for susceptibility to lysis by CTL
A2 264 at an E/T of 13:1 in a 6-h 51Cr-
release assay. The HPLC profile (absor-
bance: —) (A: first HPLC separation of
natural peptide extracts) and the specific
lysis (shaded columns) of T2 targets sensi-
tized with individual HPLC fractions
obtained from the rechromatography of natural peptides (A), 2 ml (fractions 8, 19, 20, and 29), and 0.2 ml (fractions 9–18 and 21–28) of HPLC fractions
obtained from the synthetic p53.264–272 (B) and p53.260–272 (C) peptides is shown.1025 Theobald et al.
flanking a peptide epitope on its processing, it would be pre-
dicted that point mutation outside of the epitope could also
interfere with its presentation (30, 36, 44, 51–56). To our
knowledge, our studies represent the first report of such a
naturally occurring mutation outside the epitope that alters
CTL recognition of a flanking peptide. In fact, the single
mutation described here interferes not only with the protea-
somal processing of putative precursor peptides, but also
with the generation of the optimal CTL epitope itself. It is at
present unclear why the R to H mutation interferes with the
COOH-terminal proteasomal cleavage. It is possible that a
change in charge and size of the flanking residue influences
the COOH-terminal cleavage site used by the proteasome.
However, as the possibility that a particular site will be pre-
ferred for proteasomal cleavage is dependent on amino acid
sequences within the epitope (31, 51), as well as on flanking
residues both up- and downstream (30, 36, 44, 51–56), it is
likely that the rules by which ligand generation is governed
are more complex and not yet understood.
Treatment of cells with IFN-g has been reported to alter
the processing kinetics, quantity, and quality of MHC class
I–bound peptide ligands by affecting the expression both of
the IFN-g–inducible proteasomal subunits (LMP2, LMP7,
and MECL-1) and the IFN-g–inducible PA28-a/b activa-
tor complex (11S regulator) of the 20S proteasome (28, 29,
41, 43, 57–69). Exposing Saos-2/273 (R to H) p53 trans-
fectants to IFN-g (10 ng/ml for 20 h) resulted in an only
partial reconstitution of lysis by CTL A2 264 (20% specific
lysis of nonpretreated Saos-2/273 cells versus 31% specific
lysis of IFN-g pretreated Saos-2/273 targets at an E/T of
20:1) (Häussler, A., and M. Theobald, unpublished obser-
vation). The molecular basis of this IFN-g–mediated partial
reconstitution of Saos-2/273 killing by CTL A2 264 on the
level of both the proteasomal subunit composition (LMP2,
LMP7, and MECL-1) and the PA28 activator (11S regula-
tor) expression is currently under investigation.
Based on these results, it may be concluded not only that
the p53 mutation at residue 273 is associated with malig-
nant transformation, but that it can also affect CTL recog-
nition in vitro and in vivo of tumor cells carrying this mu-
tation. It is tempting to speculate that cells harboring this
mutation may have a competitive edge for growth in
A*02011 individuals by evading CTL recognition (70).
Several other reports have shown that vaccination of mice
with the intact p53 protein expressed in a viral vector or
with p53 peptides pulsed onto dendritic cells can prevent
growth in vivo of tumors expressing high levels of p53 (5,
7). Furthermore, recent studies have demonstrated the abil-
ity of p53.264–272 epitope–specific Hu CTL to lyse squa-
mous cancer cells (6). Thus, knowledge not only of the an-
tigenic epitopes of p53, but also of the biological role of
their sequence context and its modulation by frequently
arising mutations may explain disease progression, and may
assist in the design of efficacious cancer vaccines.
We thank Jack Bennink and Jonathan Yewdell for providing recombinant vaccinia viruses, and Ilse Drung
(Humboldt University) for excellent technical assistance.
Supported by grants from the Deutsche Forschungsgemeinschaft to M. Theobald (SFB 432 A3), T. Ruppert
and U.H. Koszinowski (SFB 469), and P.-M. Kloetzel (DFG KL 427/9-2); the “Stiftung Rheinland-Pfalz
für Innovation” to M. Theobald; the European Community to U.H. Koszinowski (PL 960505) and P.-M.
Kloetzel (BMH 4-2-CT-96-0447); and the National Institutes of Health to L.A. Sherman (CA-57855 and
CA-25803). M. Theobald is a fellow of the Stipendienprogramm Infektionsbiologie provided by the Ger-
man Cancer Research Center (DKFZ) and funded by the German Ministry for Education and Research
(BMBF).
Address correspondence to Linda A. Sherman, The Scripps Research Institute, Department of Immunology,
IMM-15, 10666 North Torrey Pines Rd., La Jolla, CA 92037. Phone: 619-784-8052; Fax: 619-784-8298;
E-mail: lsherman@scripps.edu
Received for publication 20 November 1997 and in revised form 25 June 1998.
References
1. Levine, A.J., J. Momand, and C.A. Finlay. 1991. The p53 tu-
mor suppressor gene. Nature. 351:453–456.
2. Hollstein, M., D. Sidransky, B. Vogelstein, and C.C. Harris.
1991. p53 mutations in human cancers. Science. 253:49–53.
3. Denissenko, M.F., A. Pao, M. Tang, and G.P. Pfeifer. 1996.
Preferential formation of benzo[a]pyrene adducts at lung can-
cer mutational hotspots in p53. Science. 274:430–432.
4. Theobald, M., J. Biggs, D. Dittmer, A.J. Levine, and L.A.
Sherman. 1995. Targeting p53 as a general tumor antigen.
Proc. Natl. Acad. Sci. USA. 92:11993–11997.
5. Roth, J., D. Dittmer, D. Rea, J. Tartaglia, E. Paoletti, and
A.J. Levine. 1996. p53 as a target for cancer vaccines: recom-
binant canarypox virus vectors expressing p53 protect mice
against lethal tumor challenge. Proc. Natl. Acad. Sci. USA. 93:
4781–4786.
6. Röpke, M., J. Hald, P. Guldberg, J. Zeuthen, L. Norgaard,
L. Fugger, A. Svejgaard, S. Van Der Burg, H.W. Nijman,
C.J.M. Melief, and M.H. Claesson. 1996. Spontaneous human1026 p53 Hotspot Retards Proteasomal Processing of a Flanking CTL Epitope
squamous cell carcinomas are killed by a human cytotoxic T
lymphocyte clone recognizing a wild-type p53-derived pep-
tide. Proc. Natl. Acad. Sci. USA. 93:14704–14707.
7. Mayordomo, J.I., D.J. Loftus, H. Sakamoto, C.M. De Ce-
sare, P.M. Appasamy, M.T. Lotze, W.J. Storkus, E. Appella,
and A.B. DeLeo. 1996. Therapy of murine tumors with p53
wild-type and mutant sequence peptide-based vaccines. J.
Exp. Med. 183:1357–1365.
8. Theobald, M., J. Biggs, J. Hernandez, J. Lustgarten, C. La-
badie, and L.A. Sherman. 1997. Tolerance to p53 by A2.1-
restricted cytotoxic T lymphocytes. J. Exp. Med. 185:833–841.
9. Vierboom, M.P.M., H.W. Nijman, R. Offringa, E.I.H. van
der Voort, T. van Hall, L. van den Broek, G.J. Fleuren, P.
Kenemans, W.M. Kast, and C.J.M. Melief. 1997. Tumor
eradication by wild-type p53-specific cytotoxic T lympho-
cytes. J. Exp. Med. 186:695–704.
10. Houbiers, J.G.A., H.W. Nijman, S.H. van der Burg, J.W.
Drijfthout, P. Kenemans, C.J. van de Velde, A. Brand, F.
Momburg, W.M. Kast, and C.J.M. Melief. 1993. In vitro in-
duction of human cytotoxic T lymphocyte responses against
peptides of mutant and wild-type p53. Eur. J. Immunol. 23:
2072–2077.
11. Nijman, H.W., J.G.A. Houbiers, S.H. van der Burg, M.P.M.
Vierboom, P. Kenemans, W.M. Kast, and C.J.M. Melief.
1993. Characterization of cytotoxic T lymphocyte epitopes
of a self-protein, p53, and a non–self-protein, influenza ma-
trix: relationship between major histocompatibility complex
peptide binding affinity and immune responsiveness to pep-
tides. J. Immunother. 14:121–126.
12. Nijman, H.W., S.H. van der Burg, M.P.M. Vierboom,
J.G.A. Houbiers, W.M. Kast, and C.J.M. Melief. 1994. p53,
a potential target for tumor-directed T cells. Immunol. Lett.
40:171–178.
13. Röpke, M., M. Regner, and M.H. Claesson. 1995. T-cell
mediated cytotoxicity against p53-protein derived peptides in
bulk and limiting dilution cultures of healthy donors. Scand.
J. Immunol. 42:98–103.
14. Rock, K.L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L.
Dick, D. Hwang, and A.L. Goldberg. 1994. Inhibitors of the
proteasome block the degradation of most cell proteins and
the generation of peptides presented on MHC class I mole-
cules. Cell. 78:761–771.
15. Groettrup, M., A. Soza, U. Kuckelkorn, and P.-M. Kloetzel.
1996. Peptide antigen production by the proteasome: com-
plexity provides efficiency. Immunol. Today. 17:429–435.
16. Lehner, P.J., and P. Cresswell. 1996. Processing and delivery
of peptides presented by MHC class I molecules. Curr. Opin.
Immunol. 8:59–67.
17. Scheffner, M., B.A. Werness, J.M. Huibregtse, A.J. Levine,
and P.M. Howley. 1990. The E6 oncoprotein encoded by
human papillomavirus types 16 and 18 promotes the degrada-
tion of p53. Cell. 63:1129–1136.
18. Maki, C.G., J.M. Huibregtse, and P.M. Howley. 1996. In
vivo ubiquitination and proteasome-mediated degradation of
p53. Cancer Res. 56:2649–2654.
19. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2
promotes the rapid degradation of p53. Nature. 387:296–299.
20. Kubbutat, M.H., S.N. Jones, and K.H. Vousden. 1997. Reg-
ulation of p53 stability by Mdm2. Nature. 387:299–303.
21. Schumacher, T.N., D.V. Kantesaria, M.T. Heemels, P.G.
Ashton-Rickardt, J.C. Shepherd, K. Früh, Y. Yang, P.A.
Peterson, S. Tonegawa, and H.L. Ploegh. 1994. Peptide
length and sequence specificity of the mouse TAP1/TAP2
translocator. J. Exp. Med. 179:533–540.
22. Momburg, F., J. Roelse, G.J. Hämmerling, and J.J. Neefjes.
1994. Peptide size selection by the major histocompatibility
complex-encoded peptide transporter. J. Exp. Med. 179:
1613–1623.
23. Van Endert, P.M., R. Tampe, T.H. Meyer, R. Tisch, J.F.
Bach, and H.O. McDevitt. 1994. A sequential model for
peptide binding and transport by the transporters associated
with antigen processing. Immunity. 1:491–500.
24. DeMars, R., R. Rudersdorf, C. Chang, J. Petersen, J.
Strandtmann, N. Korn, B. Sidwell, and H.T. Orr. 1985. Mu-
tations that impair a posttranscriptional step in expression of
HLA-A and -B antigens. Proc. Natl. Acad. Sci. USA. 82:
8183–8187.
25. Dittmer, D., S. Pati, G. Zambetti, S. Chu, A.K. Teresky, M.
Moore, C. Finlay, and A.J. Levine. 1993. Gain of function
mutations in p53. Nat. Genet. 4:42–46.
26. Anton, L.C., J.W. Yewdell, and J.R. Bennink. 1997. MHC
class I-associated peptides produced from endogenous gene
products with vastly different efficiencies. J. Immunol. 158:
2535–2542.
27. Earl, P.L., A.W. Hugin, and B. Moss. 1990. Removal of
cryptic poxvirus transcription termination signals from the
human immunodeficiency virus type 1 envelope gene en-
hances expression and immunogenicity of a recombinant vac-
cinia virus. J. Virol. 64:2448–2451.
28. Kuckelkorn, U., S. Frentzel, R. Kraft, S. Kostka, M. Groet-
trup, and P.-M. Kloetzel. 1995. Incorporation of major his-
tocompatibility complex–encoded subunits LMP2 and LMP7
changes the quality of the 20S proteasome polypeptide pro-
cessing products independent of interferon-g. Eur. J. Immu-
nol. 25:2605–2611.
29. Dick, T.P., T. Ruppert, M. Groettrup, P.-M. Kloetzel, L.
Kuehn, U.H. Koszinowski, S. Stefanovic, H. Schild, and
H.-G. Rammensee. 1996. Coordinated dual cleavages in-
duced by the proteasome regulator PA28 lead to dominant
MHC ligands. Cell. 86:253–262.
30. Eggers, M., B. Boes-Fabian, T. Ruppert, P.-M. Kloetzel, and
U.H. Koszinowski. 1995. The cleavage preference of the
proteasome governs the yield of antigenic peptides. J. Exp.
Med. 182:1865–1870.
31. Ossendorp, F., M. Eggers, A. Neisig, T. Ruppert, M. Groet-
trup, A. Sijts, E. Mengede, P.-M. Kloetzel, J. Neefjes, U.
Koszinowski, and C. Melief. 1996. A single residue exchange
within a viral CTL epitope alters proteasome-mediated deg-
radation resulting in lack of antigen presentation. Immunity. 5:
115–124.
32. Storkus, W.J., H.J. Zeh III, M.J. Maeurer, R.D. Salter, and
M.T. Lotze. 1993. Identification of melanoma peptides rec-
ognized by class I restricted tumor infiltrating T lymphocytes.
J. Immunol. 151:3719–3727.
33. Itoh, T., W.J. Storkus, E. Gorelik, and M.T. Lotze. 1994.
Partial purification of murine tumor-associated peptide epi-
topes common to histologically distinct tumors, melanoma
and sarcoma, that are presented by H-2Kb molecules and rec-
ognized by CD81 tumor-infiltrating lymphocytes. J. Immu-
nol. 153:1202–1215.
34. Lustgarten, J., M. Theobald, C. Labadie, D. LaFace, P. Peter-
son, M.L. Disis, M.A. Cheever, and L.A. Sherman. 1997.
Identification of Her-2/Neu CTL epitopes using double
transgenic mice expressing HLA-A2.1 and human CD8.
Hum. Immunol. 52:109–118.
35. Sherman, L.A., M. Theobald, D. Morgan, J. Hernandez, I.1027 Theobald et al.
Bacik, J. Yewdell, J. Bennink, and J. Biggs. 1998. Strategies
for tumor elimination by cytotoxic T lymphocytes. Crit. Rev.
Immunol. 18:47–54.
36. Shastri, N., T. Serwold, and F. Gonzalez. 1995. Presentation
of endogenous peptide/MHC class I complexes is profoundly
influenced by specific C-terminal flanking residues. J. Immu-
nol. 155:4339–4346.
37. Roelse, J., M. Gromme, F. Momburg, G. Hämmerling, and
J. Neefjes. 1994. Trimming of TAP-translocated peptides in
the endoplasmic reticulum and in the cytosol during recy-
cling. J. Exp. Med. 180:1591–1597.
38. Snyder, H.L., J.W. Yewdell, and J.R. Bennink. 1994. Trim-
ming of antigenic peptides in an early secretory compart-
ment.  J. Exp. Med. 180:2389–2394.
39. Elliott, T., A. Willis, V. Cerundolo, and A. Townsend. 1995.
Processing of major histocompatibility class I–restricted anti-
gens in the endoplasmic reticulum. J. Exp. Med. 181:1481–
1491.
40. Craiu, A., T. Akopian, A. Goldberg, and K.L. Rock. 1997.
Two distinct proteolytic processes in the generation of a ma-
jor histocompatibility complex class I–presented peptide.
Proc. Natl. Acad. Sci. USA. 94:10850–10855.
41. Boes, B., H. Hengel, T. Ruppert, G. Multhaup, U.H. Koszi-
nowski, and P.-M. Kloetzel. 1994. Interferon g stimulation
modulates the proteolytic activity and cleavage site preference
of 20S mouse proteasomes. J. Exp. Med. 179:901–909.
42. Villanueva, M.S., P. Fischer, K. Feen, and E.G. Pamer. 1994.
Efficiency of MHC class I antigen processing: a quantitative
analysis. Immunity. 1:479–489.
43. Groettrup, M., T. Ruppert, L. Kuehn, M. Seeger, S. Stan-
dera, U. Koszinowski, and P.-M. Kloetzel. 1995. The inter-
feron-gamma-inducible 11S regulator (PA28) and the LMP2/
LMP7 subunits govern the peptide production by the 20S
proteasome in vitro. J. Biol. Chem. 270:23808–23815.
44. Niedermann, G., S. Butz, H.G. Ihlenfeldt, R. Grimm, M.
Lucchiari, H. Hoschützky, G. Jung, B. Maier, and K. Eich-
mann. 1995. Contribution of proteasome-mediated proteoly-
sis to the hierarchy of epitopes presented by major histocom-
patibility complex class I molecules. Immunity. 2:289–299.
45. Niedermann, G., G. King, S. Butz, U. Birsner, R. Grimm, J.
Shabanowitz, D.F. Hunt, and K. Eichmann. 1996. The pro-
teolytic fragments generated by vertebrate proteasomes:
structural relationships to major histocompatibility complex
class I binding peptide. Proc. Natl. Acad. Sci. USA. 93:8572–
8577.
46. Koup, R.A. 1994. Virus escape from CTL recognition. J.
Exp. Med. 180:779–782.
47. de Campos-Lima, P.O., V. Levitsky, J. Brooks, S.P. Lee, L.F.
Hu, A.B. Rickinson, and M.G. Masucci. 1994. T cell re-
sponses and virus evolution: loss of HLA A11-restricted CTL
epitopes in Epstein-Barr virus isolates from highly A11-posi-
tive populations by selective mutation of anchor residues. J.
Exp. Med. 179:1297–1305.
48. Goulder, P.J., A.K. Sewell, D.G. Lalloo, D.A. Price, J.A.
Whelan, J. Evans, G.P. Taylor, G. Luzzi, P. Giangrande,
R.E. Phillips, and A.J. McMichael. 1997. Patterns of immu-
nodominance in HIV-1-specific cytotoxic T lymphocyte re-
sponses in two human histocompatibility leukocyte antigens
(HLA)-identical siblings with HLA-A*0201 are influenced by
epitope mutation. J. Exp. Med. 185:1423–1433.
49. Moskophidis, D., and R.M. Zinkernagel. 1995. Immunobi-
ology of cytotoxic T-cell escape mutants of lymphocytic
choriomeningitis virus. J. Virol. 69:2187–2193.
50. Price, D.A., P.J. Goulder, P. Klenerman, A.K. Sewell, P.J.
Easterbrook, M. Troop, C.R. Bangham, and R.E. Phillips.
1997. Positive selection of HIV-1 cytotoxic T lymphocyte
escape variants during primary infection. Proc. Natl. Acad. Sci.
USA. 94:1890–1895.
51. Hahn, Y.S., C.S. Hahn, V.L. Braciale, T.J. Braciale, and
C.M. Rice. 1992. CD81 T cell recognition of an endoge-
nously processed epitope is regulated primarily by residues
within the epitope. J. Exp. Med. 176:1335–1341.
52. Eisenlohr, L.C., J.W. Yewdell, and J.R. Bennink. 1992.
Flanking sequences influence the presentation of an endoge-
nously synthesized peptide to cytotoxic T lymphocytes. J.
Exp. Med. 175:481–487.
53. Del Val, M., H.-J. Schlicht, T. Ruppert, M.J. Reddehase,
and U.H. Koszinowski. 1991. Efficient processing of an anti-
genic sequence for presentation by MHC class I molecules
depends on its neighboring residues in the protein. Cell. 66:
1145–1153.
54. Bergmann, C.C., L. Tong, R. Cua, J. Sensintaffar, and S.
Stohlman. 1994. Differential effects of flanking residues on
presentation of epitopes from chimeric peptides. J. Virol. 68:
5306–5310.
55. Bergmann, C.C., Q. Yao, C.-K. Ho, and S.L. Buckwold.
1996. Flanking residues alter antigenicity and immunogenic-
ity of multi-unit CTL epitopes. J. Immunol. 157:3242–3249.
56. Yellen-Shaw, A.J., E.J. Wherry, G.C. Dubois, and L.C.
Eisenlohr. 1997. Point mutation flanking a CTL epitope ab-
lates in vitro and in vivo recognition of a full-length viral
protein. J. Immunol. 158:3227–3234.
57. Arnold, D., P. Driscoll, M. Androlewicz, E. Hughes, P.
Cresswell, and T.A. Spiess. 1992. Proteasome subunits en-
coded in the MHC are not generally required for the pro-
cessing of peptides bound by MHC class I molecules. Nature.
360:171–173.
58. Momburg, F., V. Ortiz-Navarrete, J. Neefjes, E. Goulmy, Y.
Vandewal, H. Spits, S.J. Powis, G.W. Butcher, J.C. Howard,
P. Walden, and G.J. Hämmerling. 1992. The proteasome
subunits encoded by the major histocompatibility complex
are not essential for antigen presentation. Nature. 360:174–177.
59. Driscoll, P., M. Brown, D. Finley, and J.J. Monaco. 1993.
MHC-linked LMP gene products specifically alter peptidase
activities of the proteasome. Nature. 365:252–264.
60. Gaczynska, M., K.L. Rock, T.A. Spiess, and A.L. Goldberg.
1993. g-interferon and expression of MHC genes regulate
peptide hydrolysis by proteasomes. Nature. 365:264–267.
61. Gaczynska, M., K.L. Rock, T.A. Spiess, and A.L. Goldberg.
1994. Peptidase activities of proteasomes are differentially
regulated by the major histocompatibility complex–encoded
genes for LMP-2 and LMP-7. Proc. Natl. Acad. Sci. USA. 91:
9213–9217.
62. Yewdell, J.W., C. Lapham, I. Bacik, T.A. Spiess, and J.R.
Bennink. 1994. MHC-encoded proteasome subunits LMP-2
and LMP-7 are not required for efficient antigen presenta-
tion. J. Immunol. 152:1163–1170.
63. Van Kaer, L., P.G. Ashton-Rickardt, M. Eichelberger, M.
Gaczynska, K. Nagashima, K.L. Rock, A.L. Goldberg, P.C.
Doherty, and S. Tonegawa. 1994. Altered peptidase and vi-
ral-specific T cell response in LMP2 mutant mice. Immunity.
1:533–541.
64. Fehling, H.J., W. Swat, C. Laplace, R. Kühn, K. Rajewsky,
U. Müller, and H. von Boehmer. 1994. MHC class I expres-
sion in mice lacking the proteasome subunit LMP-7. Science.
265:1234–1237.1028 p53 Hotspot Retards Proteasomal Processing of a Flanking CTL Epitope
65. Cerundolo, V., A. Kelly, T. Elliott, J. Trowsdale, and A.
Townsend. 1995. Genes encoded in the major histocompati-
bility complex affecting the generation of peptides for TAP
transport. Eur. J. Immunol. 25:554–562.
66. Sibille, C., K.G. Gould, K. Willard-Gallo, S. Thomson, A.J.
Rivett, S.J. Powis, G.W. Butcher, and P. De Baetselier.
1995. LMP21 proteasomes are required for the presentation
of specific antigens to cytotoxic T lymphocytes. Curr. Biol. 5:
923–930.
67. Groettrup, M., R. Kraft, S. Kostka, S. Standera, R. Stoh-
wasser, and P.-M. Kloetzel. 1996. A third interferon-g–induced
subunit exchange in the 20S proteasome. Eur. J. Immunol. 26:
863–869.
68. Groettrup, M., S. Standera, R. Stohwasser, and P.M. Kloet-
zel. 1997. The subunits MECL-1 and LMP2 are mutually re-
quired for incorporation into the 20S proteasome. Proc. Natl.
Acad. Sci. USA. 94:8970–8975.
69. Niedermann, G., R. Grimm, E. Geier, M. Maurer, C. Re-
alini, C. Gartmann, J. Soll, S. Omura, M.C. Rechsteiner, W.
Baumeister, and K. Eichmann. 1997. Potential immunocom-
petence of proteolytic fragments produced by proteasomes
before evolution of the vertebrate immune system. J. Exp.
Med. 185:209–220.
70. Wiedenfeld, E.A., M. Fernandez-Vina, J.A. Berzofsky, and
D.P. Carbone. 1994. Evidence for selection against human
lung cancers bearing p53 missense mutations which occur
within the HLA A*0201 peptide consensus motif. Cancer Res.
54:1175–1177.